[Advancing 131I-MIBG Therapy-New Horizons in Treating Malignant Pheochromocytoma and Paraganglioma].

Abstract

131I-MIBG radionuclide therapy for the recurrence case of phaeochromocytoma and paraganglioma has been used in Europe from the 1980s, and in Japan from the 1990s by patient's expense. 131I-MIBG therapy for malignant phaeochromocytoma and paraganglioma became the insurance adaptation in Japan in 2022, however there are not enough number of the facilities that can enforce this treatment now. Because radioactivity is given by oneself after the treatment, the patient is hospitalized in the lead cover room that is a radiation therapy sickroom. Cooperation of the medical staff having expertise to nuclear medicine treatment is necessary. Although it is not strong, as for the 131I-MIBG therapy, the cytoreductive effect controls progress and is effective in the decrease in serum catecholamine level. In this report, we speak a summary of the 131I-MIBG therapy, a fact of the treatment, toxicities, curative effect, present situation and the future prospects.